Dr. Laubach on the Efficacy of Daratumumab in Myeloma

Jacob Laubach, MD, MPP
Published Online: Tuesday, December 10, 2013

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute and an Instructor in Medicine at the Harvard Medical School, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

At doses of 4 mg/kg or higher, the overall response rate, including minimal response, was over 60%, Laubach states. Additionally, the rate of partial response or better was in the range of 40% to 45%, as defined as a 50% reduction in monoclonal protein.

In general, daratumumab was well tolerated. As expected, infusion reactions were observed, specifically early on in the trial. The leading infusion reaction was bronchospasm, Laubach notes. In general, the early administration of supportive medications, such as corticosteroids, seems to help alleviate some of these conditions, making the drug overall well tolerated.

<<< View more from the 2013 ASH Meeting

Online CME Activities
Free CME from PER
Evolving Management Strategies for Triple-Negative Breast Cancer
Community Practice Connections™: Current and Emerging Strategies in the Management of Early Breast Cancer
Cancer Summaries and Commentaries™: Update from Vienna: Advances in the Treatment of Gastrointestinal Cancers
Advances in Targeted Therapy: The Emerging Role of PARP Inhibitors in the Treatment of Cancers
More Reading